Abstract
Phospholemman (PLM), a member of the FXYD family of regulators of ion transport, is a major sarcolemmal substrate for protein kinases A and C in cardiac and skeletal muscle. In the heart, PLM co-localizes and co-immunoprecipitates with Na + -K + -ATPase, Na + /Ca 2+ exchanger and L-type Ca 2+ channel. Functionally, when phosphorylated at serine 68 , PLM stimulates Na + -K + -ATPase but inhibits Na + /Ca 2+ exchanger in cardiac myocytes. In heterologous expression systems, PLM modulates the gating of cardiac L-type Ca 2+ channel. Therefore, PLM occupies a key modulatory role in intracellular Na + and Ca 2+ homeostasis and is intimately involved in regulation of excitation-contraction (EC) coupling. Genetic ablation of PLM results in a slight increase in baseline cardiac contractility and prolongation of action potential duration. When hearts are subjected to catecholamine stress, PLM minimizes the risks of arrhythmogenesis by reducing Na + overload and simultaneously preserves inotropy by inhibiting Na + /Ca 2+ exchanger.
In heart failure, both expression and phosphorylation state of PLM are altered and may partly account for abnormalities in EC coupling. The unique role of PLM in regulation of Na + -K + -
Introduction
Phospholemman (PLM) was initially identified by Larry Jones in 1985 (58) as a 15-kDa sarcolemmal (SL) protein that is phosphorylated in response to isoproterenol and is distinct from phospholamban (PLB)(58). Follow-up studies indicated that this 15-kDa SL protein is also phosphorylated by protein kinase (PK) C (59) and α-adrenergic agonists (38). In 1991, this 15-kDa SL phosphoprotein was purified, the complete protein sequence determined by Edman degradation, the cDNA cloned, and the name "phospholemman" was coined (53). In 1997, the human PLM gene is localized to chromosome 19q13.1 (11) .
PLM is synthesized as a 92 amino acid peptide containing at its N-terminus a 20 amino acid signal peptide which is cleaved off during processing. The mature protein contains 72 amino acid residues with a calculated molecular weight of 8409, but a mobility of ~15 kDa in SDS-PAGE gels. The first 17 amino acid residues lie in the extracellular domain. The transmembrane (TM) region contains 20 amino acids (residues 18-37) while the remaining 35 amino acids (residues 38-72) at the C-terminus are in the cytoplasm. Palmer et al. (53) also noted sequence homology between PLM and γ-subunit of Na + -K + -ATPase, as well as a short region of sequence 4 similarity between PLM (at its C-terminus facing the cytoplasm) and PLB (at its N-terminus also facing the cytoplasm). This region of sequence similarity (RSSIRRLST 69 in PLM and RSAIRRAST 17 in PLB) contains serines and threonines that are potential phosphorylation sites.
Indeed, serine 68 in PLM and serine 16 in PLB are phosphorylated by PKA (67, 79) .
The extracellular N-terminus of PLM contains a FXYD motif, and the cytoplasmic tail of dog, human and rat PLM contains 3 serines (at residues 62, 63 and 68) and 1 threonine (at residue 69) but threonine 69 is replaced by serine in mouse PLM. By nuclear magnetic resonance (NMR) (23) and infrared spectroscopy (2) , the TM domain of PLM reconstituted in liposomes is an α-helix with a maximum tilt of 15-17 0 . Specifically, NMR spectroscopic studies of highly purified PLM in model micelles indicate that the molecule consists of 4 α-helices: H1 (residues 12-17) is in the extracellular N-terminus, H2 (residues 22-38) is the main TM helix followed by the short H3 (residues 39-45), and H4 (residues 60-68) in the C-terminus is connected to H3 by a flexible linker ( Fig. 1 ) (76) . In vivo, PKA phosphorylates serine 68 while PKC phosphorylates serine 63 and serine 68 of PLM (79) . In vitro studies using PLM fragments suggest that PKA also phosphorylates serine 63 while PKC phosphorylates threonine 69 (25) . In adult rat myocytes, ∼46%
of serine 68 and ∼16% of serine 63 are estimated to be phosphorylated in the resting state (69) .
Using phospho-specific anti-PLM antibodies (25, 62), ∼30-40% of PLM in adult rat myocytes (25, 89) and ∼25% of PLM in guinea pig myocytes (66) are phosphorylated under basal conditions. In transfected HEK293 cells, ∼30-45 % of exogenous PLM is phosphorylated under resting conditions (92).
Based on observations on Xenopus oocytes in which PLM is overexpressed, Randall
Moorman suggested that PLM is a hyperpolarization-activated anion-selective channel (46).
When reconstituted in lipid bilayers, PLM forms a channel that is highly selective for taurine 5 (12) and is thought to be involved in regulation of cell volume in non-cardiac tissues (15, 47) .
The function of PLM in the heart remains unknown until the dawning of the 21 st century.
Phospholemman: Founding Member of the FXYD Family of Regulators of Ion Transport
In 2000, Kathy Sweadner described the FXYD family of regulators of ion transport (73) , of which PLM is the first cloned member (FXYD1 In 2002, Kaethi Geering demonstrated that PLM co-immunoprecipitates with α-subunits of Na + -K + -ATPase in bovine sarcolemma (14) . In isolated adult rat cardiac myocytes, PLM colocalizes with α-subunits of Na + -K + -ATPase (Fig. 2) . When co-expressed with α-and β-subunits There are 4 isoforms of the catalytic α-subunits of Na + -K + -ATPase and expression of a particular α-isoform is both tissue-and species-dependent (7). Human (43, 85) and rabbit (8) hearts are known to express α1-, α2-and α-3 isoforms while rodent hearts express only α1-(ouabain-resistant) and α2-isoforms of Na + -K + -ATPase (4, 66, 72, 80) . In both adult rat and mouse ventricles, the ouabain-sensitive α2-subunit is preferentially localized to the t-tubules (4, 74) and its activity represents <25% of total Na + -K + -ATPase activities (4, 72, 80) . PLM coimmunoprecipitates all 3 α-subunits of Na + -K + -ATPase in human and rabbit (8), α1-and α2-subunits in mouse (80) and bovine (14) , but only α1-subunit in rat (24) and guinea pig (66) hearts. In both wild-type (WT) mouse (80) and guinea pig (66) ventricular myocytes, PLM regulates the activity of α1-but not α2-isoform of Na + -K + -ATPase. This conclusion must be tempered with the recent finding that in "SWAP" mouse (21) in which the ouabain affinities of the α-subunits are reversed, PLM regulates the apparent affinities for Na + of both α1-and α2-subunitis of Na + -K + -ATPase (9) . Together with observations made on Xenopus oocytes heterologously expressing PLM and Na + -K + -ATPase (6, 14) , it is likely the PLM regulates both α1-and α2-subunits of Na + -K + -ATPase.
Cardiac Excitation-Contraction Coupling
Both α1-(21) and α2-subunits (74) of Na + -K + -ATPase have been implicated in the control of cardiac contractility. Therefore, modulation of Na + -K + -ATPase activity suggests an important role for PLM in regulation of inotropy. We will give a brief overview of cardiac excitation-contraction coupling (Fig. 3) In addition, PLM co-immunoprecipitates with NCX1 in transfected HEK293 cells (1), pig sarcolemmal vesicles (1) and guinea pig ventricular myocyte membranes (82) . In cardiac myocytes isolated from PLM-null mice, I NaCa was higher in PLM-null myocytes (87) showed that PLM interacts with NCX1 at 2 distinct regions encompassing residues 238-270 and 300-328 (92).
There are significant differences between the mechanisms by which PLM regulates the activities of NCX1 and Na + -K + -ATPase. First, phosphorylation of PLM at serine 68 ] i transient and contraction amplitudes (18, 80) . Indeed, when hearts in vivo are stressed with maximal doses of isoproterenol, inotropy (+dP/dt) rises to a peak within 2 minutes followed by decline in WT but not PLM-null hearts (Fig. 4) . Therefore, when hearts are under duress, one of the major functions of PLM is to limit Na + and Ca 2+ overload, thereby minimizing the risks of arrhythmogenesis apparently at the expense of reduced inotropy.
On the other hand, reduced cardiac contractility under conditions of fight or flight is clearly not in the best interests of the organism. In 2006 we proposed a coordinated paradigm in which PLM, upon phosphorylation at serine 68 Acute exercise (treadmill running) in rats increases sarcolemmal PLM in skeletal muscle by 200-350% due to translocation, but phosphorylation at serine 68 appears not the be altered (60) .
When senescent rats (26 months-old) are subjected to endurance treadmill running for [13] [14] weeks, PLM in skeletal muscle is increased by 150% when compared to sedentary senescent rats (61) . In addition, increased association of PLM with α1-subunit of Na + -K + -ATPase in skeletal muscle of senescent rats (as compared to young rats) is decreased with endurance treadmill running (61).
In 2002, using cDNA microarrays containing 86 known genes and 989 unknown cDNAs, Sehl et al. (64) are the first to report that PLM is 1 of only 19 genes to increase after myocardial infarction (MI) in the rat. We confirmed that PLM protein levels increased 2.4-and 4-fold at 3 and 7 days post-MI, respectively, in the rat (89 Dominant-negative mutation in FXYD2 (γ-subunit of Na + -K + -ATPase) causes defective routing to the plasma membrane and is the cause of primary renal hypomagnesemia (44).
Increased MAT-8 (FXYD3) expression is associated with tumor progression in human breast, prostate and colorectal cancers (84) . Likewise, dysadherin (FXYD5) expression is altered in a wide variety of human cancers, including but not limited to breast, gastrointestinal stromal, head and neck, papillary thyroid, colorectal, non-small cell lung, and testicular cancers, and also epitheliod sarcoma and malignant melanoma (50).
Future Directions
The physiological role of PLM on regulation of L-type Ca 2+ channel needs to be established in its natural environment. The stoichiometry of interaction between PLM and Na + -K + -ATPase, PLM and Na + /Ca 2+ exchanger, and PLM and L-type Ca 2+ channel, remains to be determined in cardiac myocytes. The role of PLM in regulating cardiac contractility in vivo, both in health and disease states, needs further investigation. This will likely require development of novel genetic models. The effects of oxidative stress and NO on both PLM and Na + -K + -ATPase are just beginning to be addressed. For effective but specific drug targeting, the precise molecular interactions between PLM and Na + -K + -ATPase, and PLM and Na + /Ca 2+ exchanger need to be mapped out. exchanger but has no effect on Na + -K + -ATPase (69, 70, 87) . Five weeks after virus injection, in vivo hemodynamics (+dP/dt) are measured in anesthetized mice (80) . Note with increasing doses of isoproterenol, KO-S68E hearts contract significantly better than KO-GFP hearts. Since isoproterenol has no effect on Na + -K + -ATPase in phospholemman-null myocytes (17, 80), [Na + ] i is similar between KO-S68E and KO-GFP hearts (data not shown). Enhanced contractility in KO-S68E hearts is therefore due to inhibition of Na + /Ca 2+ exchanger by the S68E mutant.
Conclusion

